Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Editorial. Potential survival benefit of resection in butterfly glioblastoma.

Colman H.

Neurosurg Focus. 2018 Jun;44(6):E5. doi: 10.3171/2018.3.FOCUS18152. No abstract available.

PMID:
29852768
2.

Introduction. Update on adult neuro-oncology.

Colman H, Westphal M, Sampson JH.

Neurosurg Focus. 2018 Jun;44(6):E1. doi: 10.3171/2018.3.FOCUS18149. No abstract available.

PMID:
29852765
3.

Mutant IDH1 Promotes Glioma Formation In Vivo.

Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL.

Cell Rep. 2018 May 1;23(5):1553-1564. doi: 10.1016/j.celrep.2018.03.133.

4.

Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy053. [Epub ahead of print]

PMID:
29660006
5.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

PMID:
29074604
6.

Development of the Electronic Social Network Assessment Program Using the Center for eHealth and Wellbeing Research Roadmap.

Reblin M, Wu YP, Pok J, Kane L, Colman H, Cohen AL, Mendivil E, Warner EL, Meyer M, Agutter J.

JMIR Hum Factors. 2017 Aug 30;4(3):e23. doi: 10.2196/humanfactors.7845.

7.

Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.

Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G.

J Neurosurg. 2018 Apr;128(4):1133-1138. doi: 10.3171/2016.12.JNS162291. Epub 2017 Jun 16.

PMID:
28621623
8.

Toward more informative biomarker-based clinical trials in glioblastoma.

Colman H.

Neuro Oncol. 2017 Jul 1;19(7):880-881. doi: 10.1093/neuonc/nox063. No abstract available.

9.

A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency.

Rengifo-Cam W, Jasperson K, Garrido-Laguna I, Colman H, Scaife C, Samowitz W, Samadder NJ.

ACG Case Rep J. 2017 Mar 1;4:e34. doi: 10.14309/crj.2017.34. eCollection 2017.

10.

Glioma Subclassifications and Their Clinical Significance.

Chen R, Smith-Cohn M, Cohen AL, Colman H.

Neurotherapeutics. 2017 Apr;14(2):284-297. doi: 10.1007/s13311-017-0519-x. Review.

11.

New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.

Karsy M, Guan J, Cohen AL, Jensen RL, Colman H.

Curr Neurol Neurosci Rep. 2017 Feb;17(2):19. doi: 10.1007/s11910-017-0722-5. Review.

PMID:
28271343
12.

Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.

Chamberlain MC, Colman H, Kim BT, Raizer J.

J Neurooncol. 2017 Feb;131(3):507-516. doi: 10.1007/s11060-016-2241-7. Epub 2017 Feb 16.

PMID:
28204914
13.

Handedness and Graspability Modify Shifts of Visuospatial Attention to Near-Hand Objects.

Colman HA, Remington RW, Kritikos A.

PLoS One. 2017 Jan 26;12(1):e0170542. doi: 10.1371/journal.pone.0170542. eCollection 2017.

14.

Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report.

Raheja A, Colman H, Palmer CA, Couldwell WT.

J Neurosurg. 2017 Nov;127(5):965-970. doi: 10.3171/2016.9.JNS161629. Epub 2016 Dec 9.

PMID:
27935362
15.

IGFBP2 expression predicts IDH-mutant glioma patient survival.

Huang LE, Cohen AL, Colman H, Jensen RL, Fults DW, Couldwell WT.

Oncotarget. 2017 Jan 3;8(1):191-202. doi: 10.18632/oncotarget.13329.

16.

Grasping remaps the distribution of visuospatial attention and enhances competing action activation.

Colman H, Remington R, Kritikos A.

Q J Exp Psychol (Hove). 2017 Sep;70(9):1892-1908. doi: 10.1080/17470218.2016.1214974. Epub 2016 Aug 6.

PMID:
27434754
17.

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.

Chen R, Cohen AL, Colman H.

Curr Treat Options Oncol. 2016 Aug;17(8):42. doi: 10.1007/s11864-016-0418-0. Review.

PMID:
27334978
18.

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD.

J Clin Oncol. 2016 Jul 20;34(21):2468-77. doi: 10.1200/JCO.2015.65.7825. Epub 2016 Jun 6.

19.

Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection.

Colman H, Berre-Scoul CL, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C.

J Virol. 2016 May 27;90(12):5846. doi: 10.1128/JVI.00507-16. Print 2016 Jun 15. No abstract available.

20.

Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.

Karsy M, Guan J, Cohen A, Colman H, Jensen RL.

Neurosurg Clin N Am. 2016 Apr;27(2):249-60. doi: 10.1016/j.nec.2015.11.002. Epub 2016 Feb 18. Review.

PMID:
27012389
21.

The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation.

Karsy M, Guan J, Jensen R, Huang LE, Colman H.

World Neurosurg. 2016 Apr;88:222-36. doi: 10.1016/j.wneu.2015.12.032. Epub 2015 Dec 25. Review.

PMID:
26724617
22.

Cranial and spinal leptomeningeal dissemination in esthesioneuroblastoma: Two reports of distant central nervous system metastasis and rationale for treatment.

Sivakumar W, Oh N, Cutler A, Colman H, Couldwell WT.

Surg Neurol Int. 2015 Nov 25;6(Suppl 25):S628-32. doi: 10.4103/2152-7806.170464. eCollection 2015.

23.

Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.

Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S.

J Neurosci. 2015 Nov 11;35(45):15097-112. doi: 10.1523/JNEUROSCI.1265-15.2015.

24.

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.

Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M.

J Neurooncol. 2016 Jan;126(2):309-16. doi: 10.1007/s11060-015-1966-z. Epub 2015 Oct 27.

25.

Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism.

Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang F.

Stem Cell Res Ther. 2015 Oct 15;6:198. doi: 10.1186/s13287-015-0174-2.

26.

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M.

Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8.

27.

Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting.

Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H.

Oncotarget. 2015 Oct 13;6(31):31007-17. doi: 10.18632/oncotarget.5219.

28.

DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.

Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H.

Acta Neuropathol Commun. 2015 Jun 20;3:34. doi: 10.1186/s40478-015-0213-3.

29.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J.

N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

30.

Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.

Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF.

Stem Cells. 2015 Aug;33(8):2400-15. doi: 10.1002/stem.2053. Epub 2015 May 27.

31.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

32.

Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression.

Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang LE.

PLoS One. 2015 Apr 20;10(4):e0125125. doi: 10.1371/journal.pone.0125125. eCollection 2015.

33.

A practical review of prognostic correlations of molecular biomarkers in glioblastoma.

Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL.

Neurosurg Focus. 2015 Mar;38(3):E4. doi: 10.3171/2015.1.FOCUS14755. Review. Erratum in: Neurosurg Focus. 2015 Jun;38(6):E13. Mark, Mahan A [corrected to Mahan, Mark A].

PMID:
25727226
34.

Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.

Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H.

Neurosurg Focus. 2015 Mar;38(3):E2. doi: 10.3171/2015.1.FOCUS14745. Review.

PMID:
25727224
35.

Glioma biology and molecular markers.

Cohen AL, Colman H.

Cancer Treat Res. 2015;163:15-30. doi: 10.1007/978-3-319-12048-5_2. Review.

PMID:
25468223
36.

Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells.

Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H.

Cancer Res. 2014 Nov 15;74(22):6731-2. doi: 10.1158/0008-5472.CAN-14-2966. No abstract available.

37.

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative.

Neuro Oncol. 2015 Feb;17(2):266-73. doi: 10.1093/neuonc/nou155. Epub 2014 Sep 19.

38.

Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS; CERN Foundation.

Neuro Oncol. 2015 Mar;17(3):440-7. doi: 10.1093/neuonc/nou162. Epub 2014 Aug 13.

39.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP.

N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.

40.

Experimental validation of 5 in-silico predicted glioma biomarkers.

Towner RA, Jensen RL, Vaillant B, Colman H, Saunders D, Giles CB, Wren JD.

Neuro Oncol. 2013 Dec;15(12):1625-34. doi: 10.1093/neuonc/not124. Epub 2013 Oct 24.

41.

A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.

Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D.

Stem Cells. 2014 Jan;32(1):301-12. doi: 10.1002/stem.1528.

42.

Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report.

Cohen AL, Salzman K, Palmer C, Jensen R, Colman H.

Case Rep Oncol. 2013 Aug 24;6(2):434-40. doi: 10.1159/000354753. eCollection 2013.

43.

Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K.

Cancer Cell. 2013 Sep 9;24(3):331-46. doi: 10.1016/j.ccr.2013.08.001. Epub 2013 Aug 29.

44.

Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.

Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR.

Cancer. 2013 Aug 1;119(15):2747-53. doi: 10.1002/cncr.28031. Epub 2013 Apr 30.

45.

Genome-wide analysis of host mRNA translation during hepatitis C virus infection.

Colman H, Le Berre-Scoul C, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C.

J Virol. 2013 Jun;87(12):6668-77. doi: 10.1128/JVI.00538-13. Epub 2013 Apr 3. Erratum in: J Virol. 2016 May 27;90(12 ):5846.

46.

IDH1 and IDH2 mutations in gliomas.

Cohen AL, Holmen SL, Colman H.

Curr Neurol Neurosci Rep. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. Review.

47.

Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.

Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK.

Cancer Res. 2013 May 15;73(10):3062-74. doi: 10.1158/0008-5472.CAN-12-2033. Epub 2013 Mar 14. Retraction in: Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H. Cancer Res. 2014 Nov 15;74(22):6731-2.

48.

Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.

Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O.

Neoplasia. 2013 Jan;15(1):73-84.

49.

Medulloblastoma: molecular classifications and prognostic associations.

Shrieve DC, Colman H.

Oncology (Williston Park). 2012 Nov;26(11):1097, 1102. No abstract available.

50.

Effective elimination of cancer stem cells by a novel drug combination strategy.

Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, Colman H, Keating MJ, Li X, Xu RH, Wang J, Huang P.

Stem Cells. 2013 Jan;31(1):23-34. doi: 10.1002/stem.1273.

Supplemental Content

Loading ...
Support Center